In conclusion, our study demonstrated that the FLT3 mutation in ALL did not affect prognosis, unlike in AML, where prognosis could be improved through HSCT and FLT3 inhibitor therapy. The gene discussed is FLT3; the disease is acute myeloid leukemia.